7 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for CG Oncology, revealing an average target of $70.14, a high estimate of $75.00, and a low estimate of $60.00. Experiencing a 3.92% decline, the current average is now lower than the previous average price target of $73.00.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive CG Oncology. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | $75.00 |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | $75.00 |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | $75.00 |
| David Dai | UBS | Announces | Buy | $60.00 | - |
| Charlie Yang | B of A Securities | Maintains | Buy | $65.00 | $65.00 |
| Gregory Renza | RBC Capital | Announces | Outperform | $66.00 | - |
| Andres Maldonado | HC Wainwright & Co. | Maintains | Buy | $75.00 | $75.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CG Oncology. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CG Oncology compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of CG Oncology's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of CG Oncology's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on CG Oncology analyst ratings.
Discovering CG Oncology: A Closer Look
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Financial Insights: CG Oncology
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: CG Oncology's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 377.78%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CG Oncology's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -47453.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): CG Oncology's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.75%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.65%, the company showcases effective utilization of assets.
Debt Management: CG Oncology's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
The Significance of Analyst Ratings Explained
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
